Dennis E. Condon Insider Information
Mr. Condon has served on our board since December 2017. He brings 35 years of experience in the plastic surgery sector, including the breast implant market as President of Mentor Aesthetics from 1990 to 1998. Most recently, Mr. Condon was the CEO and President of Nuvesse Skin Therapies, a venture-backed cosmeceutical skincare company serving the U.S. medical device and retail skin care markets, until its sale to a Korean pharmaceuticals company in 2016. Previous to Nuvesse, he was CEO and President of Merz Aesthetics, Inc. and President and Chief Business Officer of BioForm Medical. BioForm was acquired by Merz Pharma in January 2010. Mr. Condon has also lead other aesthetic companies, acting as CEO of a cosmetic laser company and CEO of a national chain of cosmetic surgery centers. Mr. Condon currently serves on the boards of two other companies in the aesthetic medical field: AirXpanders Inc., a unique breast reconstruction device, and Suneva Medical Inc., which commercializes the longest lasting dermal filler for facial fine lines and wrinkles. Mr. Condon has a BS in Biological Sciences from the University of California, Davis.
What is Dennis E. Condon's net worth?
The estimated net worth of Dennis E. Condon is at least $620,640.00 as of June 9th, 2021. Mr. Condon owns 9,000 shares of Establishment Labs stock worth more than $620,640 as of September 26th. This net worth approximation does not reflect any other assets that Mr. Condon may own. Learn More.
How do I contact Dennis E. Condon?
The corporate mailing address for Mr. Condon and other Establishment Labs executives is Building B15 and 25 Coyol Free Zone, Alajuela G2, . Establishment Labs can also be reached via phone at (062) 434-2400 and via email at [email protected]
Has Dennis E. Condon been buying or selling shares of Establishment Labs?
Dennis E. Condon has not been actively trading shares of Establishment Labs during the last ninety days. Most recently, Dennis E. Condon sold 9,000 shares of the business's stock in a transaction on Wednesday, June 9th. The shares were sold at an average price of $79.01, for a transaction totalling $711,090.00. Following the completion of the sale, the director now directly owns 9,000 shares of the company's stock, valued at $711,090.
Who are Establishment Labs' active insiders?
Are insiders buying or selling shares of Establishment Labs?
During the last twelve months, Establishment Labs insiders bought shares 1 times. They purchased a total of 350 shares worth mmore than $20,989.50. During the last twelve months, insiders at the sold shares 25 times. They sold a total of 148,152 shares worth mmore than $7,043,199.64. The most recent insider tranaction occured on September, 10th when Dennis E. Condon Director bought 9,000 shares worth more than $661,500.00. Insiders at Establishment Labs own 13.1 % of the company.
Information on this page was last updated on 9/10/2021.
Dennis E. Condon Insider Trading History at Establishment Labs
|Transaction Date||Buy/Sell||Number of Shares||Average Share Price||Total Transaction||Shares Held After Transaction||Details|
Establishment Labs Company Overview
Establishment Labs Holdings, Inc. is a technology company, which engages in the design, development, manufacture, and marketing of silicone breast implants. It operates through the following geographical segments: Europe, Latin America, Asia Pacific and Middle East, and Other. The firm's products include Motiva Implants, Motiva Flora Tissue Expander, Divina, and Puregraft. The company was founded by Juan Jose Chacon-Quiros in 2004 and is headquartered in Alajuela, Costa Rica.
50 Day Range
2 Week Range